Drug Profile
BMS 599626
Alternative Names: AC480; BMS599626Latest Information Update: 23 Jul 2015
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Ambit Biosciences Corporation; Bristol-Myers Squibb
- Class Antineoplastics; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Glioma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 23 Jul 2015 Discontinued - Phase-I for Breast cancer, Glioma, Non-small cell lung cancer and Solid tumours (Combination therapy) in USA after October 2013 (IV)
- 22 Jun 2015 Ambit Biosciences withdraws phase-I trial in Solid tumours in USA prior to enrolment (Combination therapy) (NCT01245543)
- 10 Nov 2014 Ambit Biosciences Corporation has been acquired by Daiichi Sankyo Company